Anticoagulants Pharmacotherapy Flashcards
What is Apixaban, Dabigatran, Edoxaban and Rivaroxaban ALL indicated for?
What is Rivaroxaban exclusively indicated for, and not the other anticoagulant?
What is Apixaban, dabigatran and Rivaroxaban only indicated for?
MAO Of DOACS
In comparison to warfarin what is the risk of intracranial haemorrhage and major bleeding with DOACS?
Bleeding is an important adverse effect, most commonly epistaxis, GI, and genitourinary haemorrhage. The risk of intracranial haemorrhage and major bleeding is less with DOACs than with warfarin.
What are other adverse effects associated with DOACS?
What reversal agent would be given in the case of DOAC overdose?
What are the C/I for DOACs?
What would the hepatic function score have to be that would make you cautious of prescribing a DOAC?
What are important PD drug-drug interactions for ALL DOACS.
What are important PK drug-drug interactions for ALL DOACS.
Baseline testing before starting DOAC?
After starting or changing DOAC dose when should Ptx be reviewed?
Which DOAC cannot be taken out of it’s blister pack?
Dabigatran [ https://www.sps.nhs.uk/home/tools/medicines-in-compliance-aids-stability-tool/]
How should you switch a person from or to another anticoagulant? (switching from warfarin to Edoxaban)
What is the dose for the Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) Apixaban.
When is dose reduction appropriate in the case of apixaban
The recommended dose of apixaban is 5 mg taken orally twice daily.
Apixaban dose for the prophylaxis of recurrent DVT and PE in adults (following completion of 6 months of anticoagulation treatment):
What is the surgical dose for knee replacement and hip replacement for Apixaban. What are the treatment duration for the respective procedures.
Knee replacement: 2.5 mg BD 10-14 days (12-24 hours after the procedure)
Hip replacement: 2.5 mg BD for 32-38 days (12-24 hours after procedure)
What is the dose for the Prevention of stroke and systemic embolism in patients
with non-valvular atrial fibrillation (NVAF) Rivaroxaban
When is dose reduction appropriate in the case of Rivaroxaban
What is the dose for the Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) Edoxaban
When is dose reduction appropriate in the case of Edoxaban
What is the dose for the Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) Dabigatran
When is dose reduction appropriate in the case of Dabigatran
Which DOAC requires a dose reduction if CrCl is 15-49 mL/min?
A. Apixaban
B. Edoxaban
C. Rivaroxaban
D. Dabigatran
(C)
Which DOAC requires a dose reduction if CrCl is 15-50 mL/min?
A. Apixaban
B. Edoxaban
C. Rivaroxaban
D. Dabigatran
(B)